An observational study in AL Amyloidosis, POEMS Syndrome and Multiple Myeloma, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia — 6 open to participants now, 6 under way, none of them phase 3. Immunoglobulin Light-chain Amyloidosis · Fondazione IRCCS Policlinico San Matteo di Pavia.
Among the 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 12th registered.
239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.
Browse Immunoglobulin Light-chain Amyloidosis studies →6 of the 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia are open now, in 6 countries. Recruiting first, the newest first:
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18–99
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Germany, Italy, Netherlands and 3 more countries
Ages 18–99
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18–99
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18–99
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18–99
By country, each count listing its studies:
Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 1
First in 2012; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 275 across 42 observational studies indexed under Immunoglobulin Light-chain Amyloidosis.
Median enrollment 28 across the 6 interventional studies, 400 across the 7 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 258 studies on the registry; 115 are open to participants now.
3 of the studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05444920Fondazione IRCCS Policlinico San Matteo di PaviaThe Italian Transthyretin Amyloidosis Web-Network | 2026-12-31 |
| NCT04839003Fondazione IRCCS Policlinico San Matteo di PaviaA Registry of AL Amyloidosis (ReAL) | 2027-05 |
| NCT07448779Fondazione IRCCS Policlinico San Matteo di PaviaInvestigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment | 2027-05-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.
Patients with biopsy-proven diagnosis of systemic AL amyloidosis, POEMS syndrome or multiple myeloma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome.
Time frame: two years
Started Nov 2025 (actual). Primary completion is estimated for Jun 2026, 7 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Immunoglobulin Light-chain Amyloidosis →
Fondazione IRCCS Policlinico San Matteo di Pavia →